THNLA-1: A DNA-Targeted bioreductive agent as chemosensitizer in vitro and in vivo

In Vivo

Volumn 10, Issue 1, 1996, Pages 49-58

  Papadopoulou, M V ^a   Ji, M ^a   Bloomer, W D ^a  

^a EVANSTON HOSPITAL   (United States)

Author keywords

Bioreductive agents; Chemoscnsitization; DNA targeting

Indexed keywords

2 NITROIMIDAZOLE DERIVATIVE; CISPLATIN; DNA; MELPHALAN; RADIOSENSITIZING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; CELL STRAIN V 79; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; HYPOXEMIA; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN;

EID: 0029938276     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Moulder JE and Rockwell S: Tumor hypoxia; its impact on cancer therapy. Cancer Metastasis Rev 5: 313-341, 1987.
2. 2 tension measurments. Cancer Res 51: 6098-6102, 1991.
3. 2 tension measurments. Cancer Res 51: 3316-3322, 1991.
4. Gatenby RA, Kassler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH and Broder GI: Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14: 831-838, 1988.
5. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26: 45-50, 1993.
6. Siemann DW: Modification of chemotherapy by nitroimidazoles. Int J Radiat Oncol Biol Phys 10: 1585-1594, 1984.
7. Grau C and Overgaard J: Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 13: 301-309, 1988.
8. Kennedy KA: Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Des 2: 181-94, 1987.
9. Sartorelli AC: Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res 48: 775-778, 1988.
10. Papadopoulou MV, Mainwaring A and Bloomer WD: Potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea's toxicity in vitro by two new bioreductive agents. Jpn J Cancer Res 83: 907-913, 1992.
11. Papadopoulou MV, Miller A, Seskey T, Epperly MW and Bloomer WD: Potentiation of antineoplastic drugs in vitro and in vivo by intercalating bioreductive agents. Radiat Oncol Investigations 1: 206-217, 1993.
12. Murray D and Meyn RE: Enhancement of the DNA cross-linking activity of melphalan by misonidazole in vivo. Br J Cancer 47: 195-203, 1983.
13. Bergleiter A, Grover J, Froese E, et al.: Membrane transport, sulfhydryl levels and DNA cross-linking in Chinese hamster ovary cell mutants sensitive and resistant to melphalan. Biochem Pharmacol 32: 293-300, 1983.
14. Dorie MJ and Brown JM: Tumor-specific, schedule-dependent interaction between Tirapazamine (SR 4233) and Cisplatin. Cancer Res 53: 4633-4636, 1993.
15. Holden SA, Teicher BA, Ara G, Herman TS and Coleman CN: Enhancement of alkylating agent activity by SR-4233 in FSaIIC Murine Fibrosarcoma. J Nat Cancer Inst 84: 187-193, 1992.
16. Papadopoulou MV, Rosenzweig HS, Doddi M and Bloomer WD: 9-[3-(2-Nitro-1-imidazolyl)propylamino-1,2,3,4-tetrahydroacridine hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1. Oncol Res 6: 439-448, 1994.
17. Rockwell SC, Kallman RF and Fajardo LF: Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst 49: 735-749, 1972.
18. Webb JL: In: Enzymes and Metabolic Inhibitors, New York, Academic Press, 1963, Vol. I, pp. 66-79 and 487-512.
19. Stell GG and Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy. The concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91, 1979.
20. Wilson WR, Sum BG, Denny WA, Vanzijl PB, Taylor ML, Chambers DM and Roberts PB: 5-Nitro-4-(N,N-dimethylamino-propylamino) quinoline (5-Nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: Comparison with nitracrine. Radiat Res 131: 257-265, 1992.
21. Siemann DW, Wolf K, Morrissey S and Wheeler KT: In vitro potentiation of BCNU activity in rat brain tumour cells pretreated with misonidazole. Br J Cancer 49: 795-799, 1984.
22. Biedermann KA, Wang J, Graham RP and Brown JM: SR 4233 cytotoxicity and metabolism in DNA repair-competant and repair-deficient cell cultures. Br J Cancer 63: 358-362, 1991.